Liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome
| Componente | Categoria |
|---|---|
| Giuseppe Nicola Viceconte | Componenti strutturati del gruppo di ricerca |
| Luigi Iuliano | Componenti strutturati del gruppo di ricerca |
Patients with acute coronary syndrome (ACS) still experience a high rate of morbidity and mortality despite optimal medical and interventional treatments. A growing body of evidence suggest that liver fibrosis (LF) is a risk factor of increased mortality in different clinical chronic diseases. The most common reasons accounting for LF are represented by cardio-metabolic risk factors, which are also frequently found in ACS patients. However, the presence of LF and its impact on clinical outcomes in patients with ACS have not been previously investigated. The main objectives of the study will be to:
- estimate the prevalence of liver fibrosis in a large cohort of consecutive patients with acute coronary syndromes (ACS) through the estimation of non-invasive scores of LF namely APRI and FIB-4 scores;
- evaluate the relationship between the presence of liver fibrosis and the extent and severity of coronary artery disease in patients undergoing percutaneous transluminal coronary angioplasty;
- investigate the relationship between LF and the incidence of in-hospital outcomes in ACS patients, such as cardiogenic shock and death.